149 related articles for article (PubMed ID: 36723649)
21. Pembrolizumab as monotherapy in locally advanced cutaneous squamous cell carcinoma.
Giri A; Bauman JR
Expert Rev Anticancer Ther; 2022 Oct; 22(10):1029-1038. PubMed ID: 36106496
[TBL] [Abstract][Full Text] [Related]
22. Epidemiology of advanced cutaneous squamous cell carcinoma.
Dessinioti C; Pitoulias M; Stratigos AJ
J Eur Acad Dermatol Venereol; 2022 Jan; 36(1):39-50. PubMed ID: 34592000
[TBL] [Abstract][Full Text] [Related]
23. Real-world outcomes of systemic therapy in locally advanced, recurrent or metastatic cutaneous squamous cell carcinoma.
Vo TT; Espirito JL; Boyd M; Gumuscu B; Chirovsky D; Robert NJ; Swaby RF; Zhou W; Cowey CL
Future Oncol; 2022 Jun; 18(17):2087-2099. PubMed ID: 35240857
[TBL] [Abstract][Full Text] [Related]
24. PD-1 Blockade With Concurrent Radiotherapy for Locally Advanced Inoperable Cutaneous Squamous Cell Carcinoma.
Joseph K; Walker J; Raziee H; Faruqi S; Smylie M
J Cutan Med Surg; 2022; 26(3):243-248. PubMed ID: 34866423
[TBL] [Abstract][Full Text] [Related]
25. Treatment approaches in immunosuppressed patients with advanced cutaneous squamous cell carcinoma.
Willenbrink TJ; Jambusaria-Pahlajani A; Arron S; Seckin D; Harwood CA; Proby CM
J Eur Acad Dermatol Venereol; 2019 Dec; 33 Suppl 8():57-60. PubMed ID: 31833603
[TBL] [Abstract][Full Text] [Related]
26. Cutaneous squamous cell carcinoma: Management of advanced and high-stage tumors.
Que SKT; Zwald FO; Schmults CD
J Am Acad Dermatol; 2018 Feb; 78(2):249-261. PubMed ID: 29332705
[TBL] [Abstract][Full Text] [Related]
27. Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial.
Hughes BGM; Munoz-Couselo E; Mortier L; Bratland Å; Gutzmer R; Roshdy O; González Mendoza R; Schachter J; Arance A; Grange F; Meyer N; Joshi A; Billan S; Zhang P; Gumuscu B; Swaby RF; Grob JJ
Ann Oncol; 2021 Oct; 32(10):1276-1285. PubMed ID: 34293460
[TBL] [Abstract][Full Text] [Related]
28. Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma: Real-World Experience in a Monographic Oncology Center.
Ríos-Viñuela E; Álvarez P; Lavernia J; Serra-Guillén C; Requena C; Bernia E; Diago A; Llombart B; Sanmartín O
Actas Dermosifiliogr; 2022 Jun; 113(6):T610-T615. PubMed ID: 35525283
[TBL] [Abstract][Full Text] [Related]
29. Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma: Real-World Experience in a Monographic Oncology Center.
Ríos-Viñuela E; Álvarez P; Lavernia J; Serra-Guillén C; Requena C; Bernia E; Diago A; Llombart B; Sanmartín O
Actas Dermosifiliogr; 2022 Jun; 113(6):610-615. PubMed ID: 35431057
[TBL] [Abstract][Full Text] [Related]
30. Overview of guideline recommendations for the management of high-risk and advanced cutaneous squamous cell carcinoma.
Dessinioti C; Stratigos AJ
J Eur Acad Dermatol Venereol; 2022 Jan; 36 Suppl 1():11-18. PubMed ID: 34855249
[TBL] [Abstract][Full Text] [Related]
31. [Treatment of locally advanced and metastatic cutaneous squamous cell carcinoma.].
Greco S; Pugliese G; Rimini M; Depenni R
Recenti Prog Med; 2021 Jun; 112(6):69e-74e. PubMed ID: 34128944
[TBL] [Abstract][Full Text] [Related]
32. Cutaneous Squamous Cell Carcinoma: A Review of High-Risk and Metastatic Disease.
Burton KA; Ashack KA; Khachemoune A
Am J Clin Dermatol; 2016 Oct; 17(5):491-508. PubMed ID: 27358187
[TBL] [Abstract][Full Text] [Related]
33. Ex vivo therapeutic screening of metastatic cSCC: A review of methodological considerations for clinical implementation.
Conley J; Perry JR; Ashford B; Ranson M
Exp Dermatol; 2024 Apr; 33(4):e15089. PubMed ID: 38659312
[TBL] [Abstract][Full Text] [Related]
34. PD-1 inhibition therapy for advanced cutaneous squamous cell carcinoma: a retrospective analysis from the University of Southern California.
In GK; Vaidya P; Filkins A; Hermel DJ; King KG; Ragab O; Tseng WW; Swanson M; Kokot N; Lang JE; Menendez L; DeClerck B; Kim G; Hu JC; Terando A; Jadvar H; Ricker C; Miller KA; Peng DH; Wysong A
J Cancer Res Clin Oncol; 2021 Jun; 147(6):1803-1811. PubMed ID: 33210210
[TBL] [Abstract][Full Text] [Related]
35. Response of advanced cutaneous squamous cell carcinoma to immunotherapy: case report.
Ashraf S; Alsharedi M
Stem Cell Investig; 2021; 8():19. PubMed ID: 34631872
[TBL] [Abstract][Full Text] [Related]
36. Cemiplimab in cutaneous squamous cell carcinomas (SCC): an overview and a clinical case.
Ghidini A; Santangelo D; Vaccaro G; Chillura M; Petrelli F
Oral Oncol; 2022 May; 128():105847. PubMed ID: 35367788
[TBL] [Abstract][Full Text] [Related]
37. Risk factors and timing of subsequent cutaneous squamous cell carcinoma in patients with cutaneous squamous cell carcinoma: A retrospective cohort study.
Rodriguez M; Beal BT; Manmohan M; Simmons E; Varra V; Xiong D; Eversman A; Briskin IN; Knackstedt T; Vidimos AT
J Am Acad Dermatol; 2021 Mar; 84(3):719-724. PubMed ID: 32861709
[TBL] [Abstract][Full Text] [Related]
38. Clinical outcomes among unresectable, locally advanced, and metastatic cutaneous squamous cell carcinoma patients treated with systemic therapy.
Cowey CL; Robert NJ; Espirito JL; Davies K; Frytak J; Lowy I; Fury MG
Cancer Med; 2020 Oct; 9(20):7381-7387. PubMed ID: 32578965
[TBL] [Abstract][Full Text] [Related]
39. Update of the Management of Cutaneous Squamous-cell Carcinoma.
Maubec E
Acta Derm Venereol; 2020 Jun; 100(11):adv00143. PubMed ID: 32346744
[TBL] [Abstract][Full Text] [Related]
40. Treatment approaches of advanced cutaneous squamous cell carcinoma.
Peris K; Piccerillo A; Del Regno L; Di Stefani A
J Eur Acad Dermatol Venereol; 2022 Jan; 36 Suppl 1():19-22. PubMed ID: 34855254
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
